ERBB2 and breast carcinoma: The other 11 patients had progressive disease (PD), and eight of them harboured PIK3CA mutations, which indicated that the anti‐HER2 treatment effectiveness was limited for advanced HER2+ breast cancer patients with PIK3CA mutations than for those with PIK3CA‐WT (100% vs.